The US securities fraud trial of Martin Shkreli, a former pharmaceutical executive who gained notoriety for jacking up the price of an HIV drug by 5,000 percent, has been delayed due to difficulties in finding impartial jurors. Shkreli, the ex-boss of Turing Pharmaceuticals, stands accused of lying ...